biogen

(redirected from Biogen Idec)
Also found in: Wikipedia.
Related to Biogen Idec: Amgen

biogen

(ˈbaɪədʒən)
n
(Biochemistry) a hypothetical protein assumed to be the basis of the formation and functioning of body cells and tissues
Mentioned in ?
References in periodicals archive ?
announced today that Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties.
In March 2011, Amunix and Biogen Idec initiated a Research and Option Agreement under which both companies would collaborate to combine Amunix s expertise in protein half-life extension and its proprietary XTEN technology with Biogen Idec s expertise in both hemophilia and engineering long-lasting coagulation factors.
s (Redwood City CA) board of directors unanimously recommended that stockholders reject Biogen Idec Inc.
Biogen Idec (NASDAQ: BIIB) has announced that the European Commission has granted marketing approval for ZEVALIN(r) (Ibritumomab tiuxetan) radioimmunotherapy.
Biogen Idec Foundation Science on the Street will make STEM more accessible and fun through inspiring researchers and innovators taking part in arts, cultural, and community events throughout Massachusetts.
Biogen Idec (NASDAQ: BIIB) today dedicated a new facility in Research Triangle Park (RTP), consolidating its 300-person Patient Services operation with the existing RTP campus.
Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 7:00 am ET.
Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies.
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs.
Biogen Idec (NASDAQ: BIIB) today announced it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three individuals, Thomas F.
Biogen Idec (Nasdaq: BIIB) today announced that an arbitration panel has issued its decision concerning the Company's collaboration agreement with Genentech, Inc.
Biogen Idec (NASDAQ: BIIB) today announced that, based on a preliminary count provided by its proxy solicitor, it appears the Company's stockholders elected Robert W.